Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
We haven't written up this one. WSJ Markets has the full story — the link below goes straight to it.